xk官网

On March 16, 2026, the Dutch Biotech Innovation Delegation’s visit to China came to a successful close. Under the theme “Deepening Exchange and Cooperation in Biotech between China and the Netherlands,” the visit brought together representatives from top Dutch research institutions, biotech companies, and relevant policy-making bodies, who engaged in in-depth discussions with multiple Chinese biotech firms and research institutes.

On March 11, 2026, under the guidance of the China Council for the Promotion of International Trade (CCPIT) of Guangzhou Development District and Huangpu District, the "Guangdong-Jiangsu Collaborative Innovation, Smart Pharma Sails Far – Biomedical Industry-Talent Integration Exchange Meeting" was successfully held at Suzhou Ascentage Pharma. The event was co-organized by the Guangzhou Development District Biomedical & Health Industry Promotion Association and the Zhongshan University Suzhou Alumni Association, and co-hosted by Canton Biologics and Suzhou Ascentage Pharma.

On March 9, under the joint guidance of the Overseas Chinese Affairs Office of the Guangzhou Municipal People’s Government and the Guangzhou Investment Development Committee Office, the “Guangzhou Connects the World – Overseas Chinese Boost the Economy” China-Thailand Entrepreneur Biotech Industry Cooperation Exchange was successfully held on Guangzhou International Bio Island. The event was hosted by Guangzhou Hi-Tech Investment Group and organized by Bio-island Company. It aimed to deepen industrial linkages between China and Thailand in the biotechnology sector, using the overseas Chinese community as a bridge to connect global

Recently, Canton Biologics (Hong Kong) Limited (“Canton Biologics (Hong Kong)”), a wholly-owned subsidiary of Canton Biologics, achieved a major milestone: its independently developed full-length recombinant human collagen project has been awarded key support under the “Enterprise Support Scheme (ESS)” of the Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region. The project is expected to receive several million yuan in dedicated funding. This marks official recognition by Hong Kong authorities of Canton Biologics (Hong Kong)’s innovation capabilities and commercial potential, while injecting strong momentum into the company’s deep commitment to the field of aging and regenerative medicine.

Guangzhou, January 23, 2026 – On a chilly spring day, over 200 government representatives, industry experts, partners, investors, and employees gathered in Guangzhou Science City to celebrate the 10th anniversary of Guangzhou Canton Biologics Biotechnology Co., Ltd. (“Canton Biologics”), a leading Chinese large-molecule CDMO. Under the theme “A Decade Together, Forging a New Future,” the event traced the company’s journey from a 300‑square‑meter lab to an internationally recognized service provider.

Though winter brings cold weather, the competition arena was filled with blazing passion! To promote interaction among colleagues from different office locations and enrich employees' after-work life, the 6th Bio-Engine "Co-Cultivation Cup" Badminton Tournament, jointly organized by the Administration Department, Bio-Engine Badminton Association, and Gaoteng Labor Union, and generously sponsored by Bio-Engine (Shanghai) Bio-Pharmaceutical Co., Ltd., concluded successfully on December 26, 2025.

On December 19, the "Antibody Process 'Intelligence' Summit – From Lean to Excellence in Industrialization Practice" themed salon, hosted by Tofflon Life Sciences, was successfully held in Guangzhou. Dr. Qianhui Liang, Director of Cell Line and Upstream Process Development at Bio-Engine, was invited to attend and delivered a keynote speech titled "Technical Challenges and Response Strategies for High-Challenge Monoclonal Antibody Development: From Hard-to-Express Antibodies to Quality Regulation and Abnormal Characterization Analysis."

Recently, under the guidance of the Guangzhou Municipal Science and Technology Bureau, the “2025 Discovering Guangzhou Unicorn Innovative Enterprises” list, organized by the Guangzhou Science and Technology Innovation Enterprise Association and co-initiated by institutions including the Guangzhou Industrial Development Research Institute, was officially announced. Following a rigorous selection process, Guangzhou Canton Biologics Technology Co., Ltd. was successfully selected for the 2025 Guangzhou “Future Unicorn” Innovative Enterprise List, owing to its outstanding technological innovation capabilities and high growth potential in the biopharmaceutical CDMO sector.

On September 23–24, 2025, the 4th BIONNOVA Beijing Innovation Forum was successfully held in Beijing. The forum focused on full‑chain innovation collaboration and alignment with clinical needs, bringing together more than 3,000 innovation decision‑makers to discuss technological breakthroughs and industrialization pathways in cutting‑edge fields such as antibody drugs, cell and gene therapy.

On September 4–5, 2025, the 9th BioCMC Conference was successfully held at the Shangri‑La Hotel in Suzhou. The conference focused on the core challenges of biologics industrialization, covering cutting‑edge areas such as AI technology applications, antibody protein drugs, stem cells, and exosomes, with in‑depth analysis of technological innovations across the entire process from early R&D to commercial production.

Recently, Canton Biologics announced a significant advancement in its collaboration with Guangzhou Lingten Biomedicine Co., Ltd. (“Lingten Bio”). The domestic Phase III clinical IND for Catumaxomab injection – a bispecific antibody transferred from Germany to Canton Biologics by Lingten Bio’s strategic partner Lindis Biotech – has been officially approved by China’s National Medical Products Administration (NMPA). The proposed indication is for the treatment of late‑stage gastric cancer patients with malignant ascites who have failed standard antitumor therapy.

At the recent themed salon “Linking Guangdong, Gathering Talent in Huangpu, Discussing Bioprocess Solutions”, Dr. Liang Qianhui, Director of Cell Line and Upstream Process Development at Canton Biologics, delivered an insightful presentation titled “Key Strategies for Building a CHO Cell Expression Platform and Enhancing Expression Levels of Different Protein Types”.